{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:51:13Z","timestamp":1787028673228,"version":"build-2736575974"},"reference-count":228,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In the past decade, novel targeted therapy approaches, such as BTK inhibitors and Bcl2 blockers, and innovative treatments that regulate the immune response against cancer cells, such as monoclonal antibodies, CAR-T cell therapy, and immunomodulatory molecules, have been established to provide support for the treatment of patients. However, drug resistance development and relapse are still major challenges in CLL treatment. Several studies revealed that non-coding RNAs have a main role in the development and progression of CLL. Specifically, microRNAs (miRs) and tRNA-derived small-RNAs (tsRNAs) were shown to be outstanding biomarkers that can be used to diagnose and monitor the disease and to possibly anticipate drug resistance and relapse, thus supporting physicians in the selection of treatment regimens tailored to the patient needs. In this review, we will summarize the most recent discoveries in the field of targeted therapy and immunotherapy for CLL and discuss the role of ncRNAs in the development of novel drugs and combination regimens for CLL patients.<\/jats:p>","DOI":"10.3390\/jcm9020593","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T08:12:22Z","timestamp":1582618342000},"page":"593","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia"],"prefix":"10.3390","volume":"9","author":[{"given":"Felice","family":"Pepe","sequence":"first","affiliation":[{"name":"Department of Cancer Biology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA"},{"name":"The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Balatti","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA"},{"name":"The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.semcancer.2010.09.003","article-title":"Molecular basis of CLL","volume":"20","author":"Pekarsky","year":"2010","journal-title":"Semin. Cancer Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1634\/theoncologist.4-5-352","article-title":"Chronic lymphocytic leukemia","volume":"4","author":"Kalil","year":"1999","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1373\/clinchem.2010.159004","article-title":"Advances in the Clinical Staging of Chronic Lymphocytic Leukemia","volume":"57","author":"Rai","year":"2011","journal-title":"Clin. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4081\/oncol.2019.400","article-title":"Prognostic significance of aberrant CD5 expression in B-cell leukemia","volume":"13","author":"Jaseb","year":"2019","journal-title":"Oncol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia","volume":"112","author":"Rassenti","year":"2008","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","article-title":"High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations","volume":"120","author":"Edelmann","year":"2012","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Stilgenbauer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.23979","article-title":"Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment","volume":"90","author":"Hallek","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"524308","DOI":"10.1155\/2012\/524308","article-title":"The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias","volume":"2012","author":"Tzifi","year":"2012","journal-title":"Adv. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/cdd.2014.87","article-title":"Role of miR-15\/16 in CLL","volume":"22","author":"Pekarsky","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","article-title":"ROR1, an embryonic protein with an emerging role in cancer biology","volume":"5","author":"Borcherding","year":"2014","journal-title":"Protein Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1093\/hmg\/4.11.2025","article-title":"The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species","volume":"4","author":"Savitsky","year":"1995","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fonc.2018.00229","article-title":"NOTCH1 Aberrations in Chronic Lymphocytic Leukemia","volume":"8","author":"Rosati","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.V94.2.748","article-title":"Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia","volume":"94","author":"Schaffner","year":"1999","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.0800121105","article-title":"MiR-15a and miR-16-1 cluster functions in human leukemia","volume":"105","author":"Calin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nature05874","article-title":"Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project","volume":"447","author":"Birney","year":"2007","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nrg3074","article-title":"Non-coding RNAs in human disease","volume":"12","author":"Esteller","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2009.02.006","article-title":"Evolution and functions of long noncoding RNAs","volume":"136","author":"Ponting","year":"2009","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Bastide, A., and David, A. (2018). Interaction of rRNA with mRNA and tRNA in Translating Mammalian Ribosome: Functional Implications in Health and Disease. Biomolecules, 8.","DOI":"10.3390\/biom8040100"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/bs.acr.2017.06.007","article-title":"Role of the tRNA-Derived Small RNAs in Cancer: New Potential Biomarkers and Target for Therapy","volume":"135","author":"Balatti","year":"2017","journal-title":"Adv. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","article-title":"The Role of Non-coding RNAs in Oncology","volume":"179","author":"Slack","year":"2019","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.1073\/pnas.1708264114","article-title":"MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia","volume":"114","author":"Rassenti","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/cdd.2009.69","article-title":"miR-15a and miR-16-1 in cancer: Discovery, function and future perspectives","volume":"17","author":"Aqeilan","year":"2010","journal-title":"Cell Death Differ."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1002\/jcp.27342","article-title":"The miR-15a\/16 gene cluster in human cancer: A systematic review","volume":"234","author":"Liu","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1158\/0008-5472.CAN-06-3613","article-title":"Tcl1 Expression in Chronic Lymphocytic Leukemia Is Regulated by miR-29 and miR-181","volume":"66","author":"Pekarsky","year":"2006","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.18632\/oncotarget.129","article-title":"Is miR-29 an oncogene or tumor suppressor in CLL?","volume":"1","author":"Pekarsky","year":"2010","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1038\/sj.onc.1210436","article-title":"mir-29 regulates Mcl-1 protein expression and apoptosis","volume":"26","author":"Mott","year":"2007","journal-title":"Oncogene"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2141.2007.06600.x","article-title":"The 13q and 11q B-cell chronic lymphocytic leukaemia-associated regions derive from a common ancestral region in the zebrafish","volume":"137","author":"Auer","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/cncr.23270","article-title":"Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia","volume":"112","author":"Lehmann","year":"2008","journal-title":"Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4161\/epi.28603","article-title":"microRNA-34b\/con chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia","volume":"9","author":"Deneberg","year":"2014","journal-title":"Epigenetics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e1327","DOI":"10.1038\/cddis.2014.270","article-title":"MicroRNA-34a: A potential therapeutic target in human cancer","volume":"5","author":"Li","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1476-4598-9-123","article-title":"MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia","volume":"9","author":"Ferracin","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.2010.1919","article-title":"Association of a MicroRNA\/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia","volume":"305","author":"Fabbri","year":"2011","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/cdd.2009.56","article-title":"The miR-34 family in cancer and apoptosis","volume":"17","author":"Hermeking","year":"2010","journal-title":"Cell Death Differ."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/leu.2013.298","article-title":"The tumor suppressor axis p53\/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: Implications for therapy in p53-defective CLL patients","volume":"28","author":"Boysen","year":"2014","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.18632\/oncotarget.2542","article-title":"AXL kinase as a novel target for cancer therapy","volume":"5","author":"Wu","year":"2014","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2018-04-845115","article-title":"miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients","volume":"132","author":"Balatti","year":"2018","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2009-06-229211","article-title":"Karyotype-specific microRNA signature in chronic lymphocytic leukemia","volume":"114","author":"Visone","year":"2009","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1182\/blood-2008-10-185686","article-title":"Aberrant regulation of pVHL levels by microRNA promotes the HIF\/VEGF axis in CLL B cells","volume":"113","author":"Ghosh","year":"2009","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.leu.2402467","article-title":"B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules","volume":"16","author":"Kay","year":"2002","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1158\/1078-0432.CCR-10-0232","article-title":"The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo","volume":"16","author":"Paesler","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood-2011-01-333484","article-title":"miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia","volume":"118","author":"Visone","year":"2011","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.mito.2011.09.001","article-title":"miR-181 targets multiple Bcl-2 family members and influences apoptosis and mitochondrial function in astrocytes","volume":"12","author":"Ouyang","year":"2012","journal-title":"Mitochondrion"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.biopha.2018.11.074","article-title":"MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2","volume":"109","author":"Zhang","year":"2019","journal-title":"Biomed Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/carcin\/bgs179","article-title":"miR-181a\/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes","volume":"33","author":"Zhu","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1182\/blood-2012-03-415737","article-title":"The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state","volume":"120","author":"Tili","year":"2012","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-6-6","article-title":"Diverse functions of miR-125 family in different cell contexts","volume":"6","author":"Sun","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1016\/j.febslet.2009.10.002","article-title":"MicroRNA 125a and its regulation of the p53 tumor suppressor gene","volume":"583","author":"Zhang","year":"2009","journal-title":"FEBS Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2013-01-478222","article-title":"Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia","volume":"122","author":"Ferrajoli","year":"2013","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2014-03-559690","article-title":"MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia","volume":"124","author":"Cui","year":"2014","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13036","DOI":"10.18632\/oncotarget.24437","article-title":"Hsa-miR-155-5p drives aneuploidy at early stages of cellular transformation","volume":"9","author":"Pagotto","year":"2018","journal-title":"Oncotarget"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2013-09-527234","article-title":"miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1","volume":"124","author":"Mraz","year":"2014","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1073\/pnas.1500010112","article-title":"TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia","volume":"112","author":"Balatti","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1073\/pnas.1604266113","article-title":"Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer","volume":"113","author":"Pekarsky","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1073\/pnas.1706908114","article-title":"tsRNA signatures in cancer","volume":"114","author":"Balatti","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"24252","DOI":"10.1073\/pnas.1913695116","article-title":"Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia","volume":"116","author":"Veneziano","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"E2110","DOI":"10.1073\/pnas.1209414109","article-title":"MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response","volume":"109","author":"Fabbri","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell\u2013derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood-2013-10-529610","article-title":"Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia","volume":"123","author":"Jia","year":"2014","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1038\/onc.2012.295","article-title":"Leukemia cell to endothelial cell communication via exosomal miRNAs","volume":"32","author":"Umezu","year":"2013","journal-title":"Oncogene"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1182\/blood-2014-12-618470","article-title":"Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling","volume":"125","author":"Yeh","year":"2015","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2119\/molmed.2014.00214","article-title":"Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia","volume":"21","author":"Stamatopoulos","year":"2015","journal-title":"Mol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2016.378","article-title":"CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D","volume":"31","author":"Bruns","year":"2017","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Farahani, M., Rubbi, C., Liu, L., Slupsky, J.R., and Kalakonda, N. (2015). CLL Exosomes Modulate the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively Enriched in miR-202-3p. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141429"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1055-9965.EPI-12-1131-T","article-title":"Targetome Profiling, Pathway Analysis and Genetic Association Study Implicate miR-202 in Lymphomagenesis","volume":"22","author":"Hoffman","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood-2014-12-618025","article-title":"Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts","volume":"126","author":"Paggetti","year":"2015","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/1381612825666190306153318","article-title":"Extracellular Vesicles as Drug Delivery Systems - Methods of Production and Potential Therapeutic Applications","volume":"25","author":"Surman","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-4939-8661-3_4","article-title":"Production of Extracellular Vesicles Loaded with Therapeutic Cargo","volume":"1831","author":"Lamichhane","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: Mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41375-018-0215-9","article-title":"Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia","volume":"33","author":"Leeksma","year":"2019","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Singh, S.P., Dammeijer, F., and Hendriks, R.W. (2018). Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol. Cancer, 17.","DOI":"10.1186\/s12943-018-0779-z"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2040620717741861","article-title":"Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia","volume":"9","author":"Itchaki","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.3747\/co.26.4345","article-title":"Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma","volume":"26","author":"Owen","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"22136","DOI":"10.1074\/jbc.M116.746842","article-title":"The Phospholipase C\u03b32Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein","volume":"291","author":"Walliser","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: Beyond Ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc2842","article-title":"Phosphoinositide signalling in cancer: Beyond PI3K and PTEN","volume":"10","author":"Bunney","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1242\/jcs.093773","article-title":"Classes of phosphoinositide 3-kinases at a glance","volume":"127","author":"Jean","year":"2014","journal-title":"J. Cell Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11899-013-0189-7","article-title":"PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia","volume":"9","author":"Chang","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","article-title":"p110, a novel phosphoinositide 3-kinase in leukocytes","volume":"94","author":"Vanhaesebroeck","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41375-018-0012-5","article-title":"Distinct roles for phosphoinositide 3-kinases \u03b3 and \u03b4 in malignant B cell migration","volume":"32","author":"Ali","year":"2018","journal-title":"Leukemia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: Interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Rodrigues, D.A., Sagrillo, F.S., and Fraga, C.A.M. (2019). Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020069"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/blood.2019001795","article-title":"Duvelisib for CLL\/SLL and follicular non-Hodgkin lymphoma","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4613-1261-1_3","article-title":"Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma","volume":"84","author":"Reed","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","article-title":"BCL-2 FAMILY: Regulators of Cell Death","volume":"16","author":"Chao","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.trecan.2016.02.005","article-title":"Novel Mechanisms of Regulation of miRNAs in CLL","volume":"2","author":"Balatti","year":"2016","journal-title":"Trends Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.3324\/haematol.2016.157669","article-title":"Role of miR-15a\/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia","volume":"102","author":"Rampazzo","year":"2017","journal-title":"Haematologica"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/cdd.2017.159","article-title":"BCL2 and miR-15\/16: From gene discovery to treatment","volume":"25","author":"Pekarsky","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1634\/theoncologist.2017-0055","article-title":"Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents","volume":"22","author":"Cheson","year":"2017","journal-title":"Oncologist"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: First Global Approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/leu.2011.218","article-title":"TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties","volume":"26","author":"Goh","year":"2012","journal-title":"Leukemia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/geno.1994.1523","article-title":"Human and Mouse Chromosomal Mapping of the Myeloid Cell Leukemia-1 Gene: MCL1 Maps to Human Chromosome 1q21, a Region That Is Frequently Altered in Preneoplastic and Neoplastic Disease","volume":"23","author":"Craig","year":"1994","journal-title":"Genomics"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"18007","DOI":"10.1038\/s41598-017-18368-w","article-title":"Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition","volume":"7","author":"Dey","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"37173","DOI":"10.18632\/oncotarget.26444","article-title":"Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy","volume":"9","author":"Sinha","year":"2018","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2010-04-001230","article-title":"The clinical application of monoclonal antibodies in chronic lymphocytic leukemia","volume":"116","author":"Jaglowski","year":"2010","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/sj.bjc.6602022","article-title":"Targeting cytotoxic T lymphocytes for cancer immunotherapy","volume":"91","author":"Maher","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_131","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JBM.S7284","article-title":"The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies","volume":"1","author":"Castillo","year":"2010","journal-title":"J. Blood Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.4049\/jimmunol.1000303","article-title":"Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab","volume":"186","author":"Bologna","year":"2011","journal-title":"J. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/OTT.S72845","article-title":"New developments in the management of chronic lymphocytic leukemia: Role of ofatumumab","volume":"9","author":"Laurenti","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1074-7613(00)80418-5","article-title":"The CD19\u2013CD21 Complex Regulates Signal Transduction Thresholds Governing Humoral Immunity and Autoimmunity","volume":"6","author":"Tedder","year":"1997","journal-title":"Immunity"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","article-title":"A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL","volume":"124","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","article-title":"Antibodies to watch in 2019","volume":"11","author":"Kaplon","year":"2019","journal-title":"mAbs"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","article-title":"Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells","volume":"98","author":"Wong","year":"2013","journal-title":"Haematologica"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00262-009-0746-z","article-title":"A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies","volume":"59","author":"Cardarelli","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1124\/jpet.110.168062","article-title":"B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody","volume":"335","author":"Herbst","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain\u2013engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","article-title":"A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"key":"ref_149","first-page":"1476","article-title":"Effect of alemtuzumab on neoplastic B cells","volume":"89","author":"Golay","year":"2004","journal-title":"Haematologica"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","article-title":"Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical","volume":"110","author":"Zhao","year":"2007","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjh.14464","article-title":"Randomized phase 2 study of otlertuzumab and bendamustineversusbendamustine in patients with relapsed chronic lymphocytic leukaemia","volume":"176","author":"Robak","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and Function of the ADP Ribosyl Cyclase\/CD38 Gene Family in Physiology and Pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/eji.1830231005","article-title":"Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages","volume":"23","author":"Funaro","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2402339","article-title":"CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia","volume":"16","author":"Naschar","year":"2002","journal-title":"Leukemia"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-18-3412","article-title":"Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia","volume":"25","author":"Manna","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.leu.2402363","article-title":"Surface antigen expression in chronic lymphocytic leukemia: Clustering analysis, interrelationships and effects of chromosomal abnormalities","volume":"16","author":"Hulkkonen","year":"2002","journal-title":"Leukemia"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3109\/10428194.2012.681655","article-title":"Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia","volume":"53","author":"Byrd","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.humpath.2005.08.005","article-title":"BAFF-R, the major B cell\u2013activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders","volume":"36","author":"Rodig","year":"2005","journal-title":"Hum. Pathol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: A target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/bloodadvances.2018025684","article-title":"Anti\u2013BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib","volume":"3","author":"McWilliams","year":"2019","journal-title":"Blood Adv."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.leukres.2011.06.021","article-title":"ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia","volume":"35","author":"Broome","year":"2011","journal-title":"Leukemia Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ijc.23587","article-title":"Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy","volume":"123","author":"DaneshManesh","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_165","first-page":"100669","article-title":"MicroRNA dysregulation and multi-targeted therapy for cancer treatment","volume":"2019","author":"Balatti","year":"2019","journal-title":"Adv. Biol. Regul."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells in Chronic Lymphoid Leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Porter, D.L., Hwang, W.-T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., Bagg, A., Marcucci, K.T., Shen, A., and Gonzalez, V. (2015). Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med.","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2018885863","article-title":"Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 T cells and impede CAR T-cell efficacy","volume":"134","author":"Martens","year":"2019","journal-title":"Blood"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000495771","article-title":"CAR-Expressing Natural Killer Cells for Cancer Retargeting","volume":"46","author":"Kloess","year":"2019","journal-title":"Transfus. Med. Hemother."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","article-title":"The Diverse Function of PD-1\/PD-L Pathway Beyond Cancer","volume":"10","author":"Qin","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2012-10-385591","article-title":"The role of B7 family molecules in hematologic malignancy","volume":"121","author":"Greaves","year":"2013","journal-title":"Blood"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Lee, H., Lee, S., and Heo, Y.-S. (2019). Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Molecules, 24.","DOI":"10.3390\/molecules24061190"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"ref_177","first-page":"E966","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Kohrt","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: A phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Mittal, A.K., Chaturvedi, N.K., Rohlfsen, R.A., Gupta, P., Joshi, A.D., Hegde, G.V., Gregory Bociek, R., and Joshi, S.S. (2013). Role of CTLA4 in the Proliferation and Survival of Chronic Lymphocytic Leukemia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070352"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1007\/s13277-015-4217-1","article-title":"Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: The possible implications for immunotherapy with CTLA-4 blocking antibody","volume":"37","author":"Ciszak","year":"2016","journal-title":"Tumour. Biol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cdon\u2019t eat me\u201d signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/15233","article-title":"CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia","volume":"5","author":"Mateo","year":"1999","journal-title":"Nat. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"20180217","DOI":"10.1098\/rstb.2018.0217","article-title":"The macrophage checkpoint CD47 : SIRP\u03b1 for recognition of \u201cself\u201d cells: From clinical trials of blocking antibodies to mechanobiological fundamentals","volume":"374","author":"Andrechak","year":"2019","journal-title":"Philos. Trans. R. Soc. Lond B Biol. Sci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2014-05-578286","article-title":"How does lenalidomide target the chronic lymphocytic leukemia microenvironment?","volume":"124","author":"Kater","year":"2014","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: Establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"24031","DOI":"10.18632\/oncotarget.15234","article-title":"Activation of NK cells and disruption of PD-L1\/PD-1 axis: Two different ways for lenalidomide to block myeloma progression","volume":"8","author":"Giuliani","year":"2017","journal-title":"Oncotarget"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/bloodadvances.2017015396","article-title":"Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: Results for CALGB 10404 (Alliance)","volume":"2","author":"Byrd","year":"2018","journal-title":"Blood Adv."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-018-3380-z","article-title":"Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide\/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): The REVLIRIT CLL-5 AGMT phase I\/II study","volume":"97","author":"Egle","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1078-0432.CCR-18-1203","article-title":"A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies","volume":"25","author":"Rasco","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1158\/1535-7163.MCT-09-0815","article-title":"BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy","volume":"9","author":"Kremmidiotis","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","article-title":"Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia","volume":"24","author":"Lamanna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1200\/JCO.2013.49.6547","article-title":"Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study","volume":"32","author":"Hillmen","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2217\/fon-2017-0574","article-title":"Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"14","author":"Hill","year":"2018","journal-title":"Future Oncol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/leu.2010.322","article-title":"The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia","volume":"25","author":"Worm","year":"2011","journal-title":"Leukemia"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2352-3026(17)30168-0","article-title":"Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Zaritskey","year":"2017","journal-title":"Lancet. Haematol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00277-019-03651-9","article-title":"Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)","volume":"98","author":"Kessler","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/2051-1426-1-S1-P43","article-title":"Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab","volume":"1","author":"Forero","year":"2013","journal-title":"J. Immunother. Cancer"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin\u2019s Lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-12-2001","article-title":"miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse Model of Lung Adenocarcinoma","volume":"72","author":"Kasinski","year":"2012","journal-title":"Cancer Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1158\/1078-0432.CCR-10-3244","article-title":"miR-34a Induces the Downregulation of Both E2F1 and B-Myb Oncogenes in Leukemic Cells","volume":"17","author":"Zauli","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41419-018-1295-1","article-title":"miR-34a: A new player in the regulation of T cell function by modulation of NF-\u03baB signaling","volume":"10","author":"Hart","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s40425-019-0670-5","article-title":"miR-34a as hub of T cell regulation networks","volume":"7","author":"Hart","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","article-title":"Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia","volume":"27","author":"Wang","year":"2015","journal-title":"Cell Signal."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3389\/fimmu.2018.02491","article-title":"MicroRNAs: Pleiotropic Regulators in the Tumor Microenvironment","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"19807","DOI":"10.18632\/oncotarget.4415","article-title":"miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the E\u00b5-TCL1 mouse model","volume":"6","author":"Bresin","year":"2015","journal-title":"Oncotarget"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jid.2018.11.007","article-title":"A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin","volume":"139","author":"Piper","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.omtn.2019.02.023","article-title":"miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma","volume":"16","author":"Misso","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1460572","DOI":"10.1155\/2019\/1460572","article-title":"Multiple Roles of Exosomal Long Noncoding RNAs in Cancers","volume":"2019","author":"Zhao","year":"2019","journal-title":"Biomed Res. Int."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2016.163337","article-title":"Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications","volume":"102","author":"Crompot","year":"2017","journal-title":"Haematologica"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2018.06.017","article-title":"Strategic design of extracellular vesicle drug delivery systems","volume":"130","author":"Armstrong","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12943-019-0975-5","article-title":"Exosomes in the tumor microenvironment as mediators of cancer therapy resistance","volume":"18","author":"Li","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-019-0970-x","article-title":"Therapy resistance mediated by exosomes","volume":"18","author":"Steinbichler","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13287-015-0232-9","article-title":"Acellular approaches for regenerative medicine: On the verge of clinical trials with extracellular membrane vesicles?","volume":"6","author":"Gessler","year":"2015","journal-title":"Stem. Cell Res. Ther."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Yamada, N.O., Heishima, K., Akao, Y., and Senda, T. (2019). Extracellular Vesicles Containing MicroRNA-92a-3p Facilitate Partial Endothelial-Mesenchymal Transition and Angiogenesis in Endothelial Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184406"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.critrevonc.2014.10.007","article-title":"Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where do we stand?","volume":"93","author":"Palma","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.3109\/10428194.2013.784969","article-title":"Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787\/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma","volume":"54","author":"Brander","year":"2013","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/2\/593\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:59:47Z","timestamp":1760173187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/2\/593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":228,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["jcm9020593"],"URL":"https:\/\/doi.org\/10.3390\/jcm9020593","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]}}}